logo-loader
RNS
Cardiogeni PLC

Cardiogeni PLC - Grant of Incentive Options over Stock

RNS Number : 6052L
Cardiogeni PLC
09 July 2026
 

9th July 2026

Cardiogeni PLC

("Cardiogeni", "CGNI" or the "Company")

 

 

Grant of Incentive Options over Stock

 

Cardiogeni (AQSE: CGNI), a UK clinical stage biotechnology company founded by 2007 Nobel Laureate Sir Martin Evans to develop and commercialise novel heart regeneration medicines, announces that, pursuant to the authorities granted to it by shareholder resolutions passed at the Annual General Meeting held on December 31st 2025, it has granted its Executive Director, Mr Ajan Reginald with 1,750,000 incentive options over shares intended to qualify as EMI options according to the below schedule.

 

Name

Role

Grant Date

Vesting Period / Price

Number of Options Granted

Total Number of Options Held

Mr Ajan Reginald

Executive Director

08/07/26

3 years / £0.001

1,750,000

1,750,000

 

The Company has made the relevant notification to HM Revenue & Customs in accordance with the applicable statutory deadline. In the event the conditions for EMI qualification are not satisfied, this option grant will be treated as an unapproved share option.

 

Following this grant, there are 4,000,000 options outstanding and 2,560,396 warrants oustanding.

 

ENDS

 

The directors of Cardiogeni accept responsibility for this announcement.

For further information please contact:

 

Cardiogeni PLC

Dr Darrin M Disley, Executive Chairman

Ajan Reginald, Executive Officer

Via First Sentinel

 

First Sentinel Corporate Finance Limited, Corporate Adviser

Brian Stockbridge

+44 020 3855 5551

 

SP Angel Corporate Finance LLP, Corporate Broker

David Hignell

Vadim Alexandre

Devik Mehta

 +44 20 3470 0470

 

 

About Cardiogeni

Founded by Nobel Laureate, Professor Sir Martin Evans, the Cardiogeni Group is developing a new class of life-saving cellular medicines. The Group's platform technology enables the creation of unique (living) cells that are engineered with a specific therapeutic function.

The Group's lead product, CLXR-001, is a patented engineered cellular medicine to treat heart failure patients which is administered during coronary artery bypass grafting surgery. The Group's novel epigenetic cellular reprogramming technology was developed in-house by Professor Sir Martin Evans and the platform along with the pipeline of medicines in development are protected by a portfolio of ~100 international patents and trademarks.

CLXR-001 targets heart failure which will affect 1 in 4 people in their lifetime and is not reversible or curable. CLXR-001 consists of a novel allogeneic (off-the-shelf) cell type, iMP cells, engineered for cardiac regeneration whose mechanism of action is to regenerate damaged heart tissue and restoration of improved heart function improving both the life expectancy and quality of life of patients.

CLXR-001 targets the cardiac market niche of CABG surgery with ~400,000 patients per year in the US alone. The Group's two follow-on products target larger cardiac market segments of stent treatment (over two million patients per year) and myocardial infarction (heart attack, over one million patients per year). Each of the products has the potential to become a first or best-in-class blockbuster ($1B in annual sales) medicine.

CLXR-001 has successfully completed an EU Phase 2 investigator sponsored clinical trial in which patients showed a statistically significant (P<0.05) improvement in all end-point targets including heart function, reduction in heart scarring and an improvement in quality of life.

CLXR-001 has received regulatory approval to begin a randomized controlled trial from the national regulatory authority of a European Union member country, and this trial has begun dosing patients with interim data expected to read-out within 30 months of Admission.

 



 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them. 

 

1. 

Details of the person discharging managerial responsibilities / person closely associated 

a) 

Name 

Ajan Reginald

2. 

Reason for the Notification 

a) 

Position/status 

Executive Director

b) 

Initial notification / Amendment 

Initial notification 

3. 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor 

a) 

Name 

Cardiogeni PLC

 

b) 

LEI 

9845000F8F59ATZD8F92

4. 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted 

a) 

Description of the Financial instrument, type of instrument 

Other - Options over ordinary shares 

  

ISIN 

GB00BTBLFC12

b) 

Nature of the transaction 

Issue of intended EMI options at £0.001 exercise price issued at Nil consideration

c) 

Price(s) and volume(s) 

Price(s)

Volume(s) 

£0.001

1,750,000

d) 

Aggregated information: 

· Aggregated volume 

· Price 

 

1,750,000

Nil

e) 

Date of the transaction 

08/07/2026

f) 

Place of the Transaction 

Outside trading venue 

 

 



 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NEXAKFBNDBKBNOK
NO INVESTMENT ADVICE

Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.

Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.

This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.

In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.

The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.

Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

FOR OUR FULL DISCLAIMER CLICK HERE

4 min read